# A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

> **NCT03460990** · PHASE3 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 116 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** VX-659/TEZ/IVA
- **DRUG:** TEZ/IVA
- **DRUG:** IVA
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03460990
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-01
- **Primary completion:** 2018-09-26
- **Final completion:** 2018-10-08
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2019-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03460990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03460990, "A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03460990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*